Icon of the Instituts for Quality and Efficiency in Health Care

[A25-71 ] Selpercatinib (RET mutant medullary thyroid cancer) – Benefit assessment according to §35a Social Code Book V

Last updated 10.10.2025

Project no.:
A25-71

Commission:
Commission awarded on 28.05.2025 by the Federal Joint Committee (GBA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Cancer

Indication:

Adults and adolescents 12 years and older with advanced rearranged during transfection-mutant medullary thyroid cancer; first-line therapy

Result of dossier assessment:

Indication of major added benefit

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

The current version 1.1 of the dossier assessment replaces version 1.0 published on 2025-09-01.

DOI:

https://doi.org/10.60584/A25-71_V1.1_en

Project no. Title Status
A24-63 Selpercatinib (solid tumours) - Benefit assessment according to § 35a Social Code Book V Commission completed
A24-62 Selpercatinib (thyroid cancer) - Benefit assessment according to § 35a Social Code Book V Commission completed
A22-106 Selpercatinib (thyroid cancer) – Benefit assessment according to §35a Social Code Book V Commission completed
A22-65 Selpercatinib (advanced NSCLC with RET fusion) – Benefit assessment according to § 35a SGB V Commission completed
A21-29 Selpercatinib (RET fusion-positive thyroid cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
A21-28 Selpercatinib (RET mutant medullary thyroid cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
A21-27 Selpercatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
A25-159 Selpercatinib (RET fusion-positive NSCLC, first line) - Benefit assessment according to § 35a Social Code Book V (expiry of the limitation period) Commission completed
A26-71 Selpercatinib (RET-mutant medullary thyroid cancer, 2 to < 12 years) – Benefit assessment according to §35a Social Code Book V Commission completed
A26-70 Selpercatinib (RET fusion-positive thyroid cancer, from 2 to < 12 years) – Benefit assessment according to §35a Social Code Book V Commission completed
A26-69 Selpercatinib (RET fusion-positive solid tumours, from 2 to < 18 years) – Benefit assessment according to §35a Social Code Book V Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page